Comparison of measles incidence in different age groups with the intensity of specific humoral immunity in healthcare workers in Moscow

Cover Image

Cite item

Full Text

Abstract

Introduction. The study of the intensity of humoral immunity to the measles virus (Paramyxoviridae: Morbillivirus) (MV) remains relevant due to the ongoing registration of the cluster cases of measles (including nosocomial cases).

The aim of the study was to analyze correlation between the intensity of the humoral immunity to measles virus and the measles incidence in different age groups of the Moscow residents.

Material and methods. A simple analytic study was carried out under the framework of measles prevention improvement program conducted in the subjects of the Russian Federation. The study included the analysis of the reasons for the increase in the proportion of seronegative individuals and the comparison of the results of seromonitoring with the data of age-related measles incidence. Throughout 2018, total 1,855 blood serum samples obtained from employees of a large hospital center in Moscow who were previously vaccinated against measles were tested for IgG antibodies (ABs) to MV. The subjects were divided into 11 groups according to their age. Statistical analysis of the obtained data was performed using nonparametric criteria.

Results and discussion. The proportion of seronegative individuals among the staff of the medical facility decreased with age, from 38.5% in persons aged 19–23 to 0% among employees aged 64 and over. Persons aged 19–43 years were the most susceptible to measles infection, which was confirmed also by the highest incidence rate at these age groups (from 6.93 to 14.03 per 100,000 population). The age group most protected against measles was those over 64 years of age, who were all seropositive and had the lowest rates of incidence. This is probably due to the fact that by this age most of them have had a measles infection and have formed a sufficient immune response. At the same time, younger individuals living in the post-elimination era have only vaccine-induced ABs to MV, the level of which declines rapidly to non-protective values in the absence of boosterization due to the exposure to the wild-type strain of the pathogen.

Conclusion. The monitoring of the MV-specific IgG- AB levels is required for employees in the medical institutions under the age of 35. Administration of the single dose of the appropriate vaccine is recommended for seronegative individuals.

About the authors

M. P. Kostinov

FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»; FSAEI HE I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of the Health of
Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-1382-9403

105064, Moscow; 119991, Moscow

Russian Federation

P. I. Zhuravlev

FBIH «The Center of Hygiene and Epidemiology in Moscow» of the Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)

Author for correspondence.
Email: pvazhurik@gmail.com
ORCID iD: 0000-0002-0331-5580

Pavel I. Zhuravlev, Medical Epidemiologist

129626, Moscow

Russian Federation

M. N. Loktionova

FSAEI HE I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of the Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-1332-519X

119991, Moscow

Russian Federation

A. D. Shmitko

FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»

Email: fake@neicon.ru
ORCID iD: 0000-0002-7280-6877

105064, Moscow

Russian Federation

V. B. Polishchuk

FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»

Email: fake@neicon.ru
ORCID iD: 0000-0003-0533-0909

105064, Moscow

Russian Federation

A. A. Tatarinchik

FBIH «The Center of Hygiene and Epidemiology in Moscow» of the Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0002-9254-2880

129626, Moscow

Russian Federation

O. A. Smirnova

FBIH «The Center of Hygiene and Epidemiology in Moscow» of the Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0002-3058-6538

129626, Moscow

Russian Federation

I. S. Fursov

FBIH «The Center of Hygiene and Epidemiology in Moscow» of the Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0001-9725-8013

129626, Moscow

Russian Federation

References

  1. Зверев В.В., Юминова Н.В. Вакцинопрофилактика вирусных инфекций от Э. Дженнера до настоящего времени. Вопросы вирусологии. 2012; 57(S1): 33–42.
  2. ВОЗ. Корь: Информационный бюллетень. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/measles (accessed December 14, 2021).
  3. Цвиркун О.В., Тихонова Н.Т., Ющенко Г.В., Герасимова А.Г. Эпидемический процесс кори в разные периоды её вакцинопрофилактики. Эпидемиология и Вакцинопрофилактика. 2015; 14(2): 80–7.
  4. Цвиркун О.В., Герасимова А.Г., Тихонова Н.Т., Ежлова Е.Б., Мельникова А.А., Дубовицкая Е.Л., и др. Заболеваемость корью в разных возрастных группах в период элиминации инфекции. Эпидемиология и Вакцинопрофилактика. 2017; 16(3): 18–25.
  5. Семененко Т.А., Ежлова Е.Б., Ноздрачёва А.В., Русакова Е.В. Особенности проявлений эпидемического процесса кори в Москве в 1992–2014 годах. Эпидемиология и Вакцинопрофилактика. 2015; 14(6): 16–22.
  6. ВОЗ. В результате всплеска заболеваемости корью в мире умерло 140 000 человек. Available at: https://www.who.int/ru/news-room/detail/05-12-2019-more-than-140-000-die-from-measles-as-cases-surge-worldwide (accessed December 14, 2021).
  7. WHO. Country slides (measles). Available at: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/Country_slides_measles.pptx?ua=1 (accessed December 14, 2021).
  8. Ноздрачёва А.В., Семененко Т.А., Асатрян М.Н., Шмыр И.С., Ершов И.Ф., Соловьёв Д.В., и др. Иммунологическая восприимчивость населения мегаполиса к кори на этапе её элиминации. Эпидемиология и Вакцинопрофилактика. 2019; 18(2): 18–26. https://doi.org/10.31631/2073-3046-2019-18-2-18-26
  9. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2017 году». Москва; 2018.
  10. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2018 году». Москва; 2019.
  11. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году». Москва; 2020.
  12. Топтыгина А.П., Андреев Ю.Ю., Смердова М.А., Наврузова Л.Н., Малеев В.В. Сопоставление гуморального иммунного ответа у взрослых, больных корью, и привитых от этой инфекции. Инфекция и иммунитет. 2021; 11(3): 517–22. https://doi.org/10.15789/2220-7619-CHI-1396
  13. Костинов М.П., Филатов Н.Н., Журавлев П.И., Гладкова Л.С., Полищук В.Б., Шмитько А.Д., и др. Уровень коллективного иммунитета к вирусу кори у сотрудников отдельной больницы в рамках государственной программы элиминации кори. Инфекция и иммунитет. 2020; 10(1): 129–36. https://doi.org/10.15789/2220-7619-LOM-690
  14. Костинов М.П., Шмитько А.Д., Соловьёва И.Л., Сависько А.А., Полищук В.Б., Рыжов А.А., и др. Необходима ли третья доза вакцины против кори – взгляд иммунолога. Журнал микробиологии, эпидемиологии и иммунобиологии. 2016; (5): 88–94. https://doi.org/10.36233/0372-9311-2016-5-88-94
  15. Gans H.A., Yasukawa L.L., Alderson A., Rinki M., DeHovitz R., Beeler J., et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J. Infect. Dis. 2004; 190(1): 83–90. https://doi.org/10.1086/421032
  16. Janaszek W., Gut W., Gay N.J. The epidemiology of measles in Poland: prevalence of measles virus antibodies in the population. Epidemiol. Infect. 2000; 125(2): 385–92. https://doi.org/10.1017/s0950268899004616
  17. Костинов М.П., Шмитько А.Д., Бочарова И.И., Черданцев А.П., Сависько А.А., Полищук В.Б. Уровень IgG-антител к вирусу кори в пуповинной крови новорождённых с учётом возраста матерей. Эпидемиология и инфекционные болезни. 2014; 19(3): 30–4.
  18. Топтыгина А.П., Мамаева Т.А., Алёшкин В.А. Особенности специфического гуморального иммунного ответа против вируса кори. Инфекция и иммунитет. 2013; 3(3): 243–50.
  19. Avramovich E., Indenbaum V., Haber M., Amitai Z., Tsifanski E., Farjun S., et al. Measles outbreak in a highly vaccinated population – Israel, July–August 2017. MMWR Morb. Mortal. Wkly Rep. 2018; 67(42): 1186–8. https://doi.org/10.15585/mmwr.mm6742a4
  20. Kang H.J., Han Y.W., Kim S.J., Kim Y.J., Kim A.R., Kim J.A., et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine. 2017; 35(33): 4126–32. https://doi.org/10.1016/j.vaccine.2017.06.058
  21. Biellik R.J., Clements C.J. Strategies for minimizing nosocomial measles transmission. Bull. World Health Organ. 1997; 75(4): 367–75.
  22. Mossong J., Muller C.P. Estimation of the basic reproduction number of measles during an outbreak in a partially vaccinated population. Epidemiol. Infect. 2000; 124(2): 273–8. https://doi.org/10.1017/s0950268899003672
  23. Mossong J., O’Callaghan C.J., Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine. 2000; 19(4-5): 523–9. https://doi.org/10.1016/s0264-410x(00)00175-4
  24. Perry R.T., Halsey N.A. The clinical significance of measles: a review. J. Infect. Dis. 2004; 189(Suppl. 1): 4–16. https://doi.org/10.1086/377712
  25. Bloch A.B., Orenstein W.A., Ewing W.M., Spain W.H., Mallison G.F., Herrmann K.L., et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics. 1985; 75(4): 676–83.
  26. Chen S.Y., Anderson S., Kutty P.K., Lugo F., McDonald M., Rota P.A., et al. Health care-associated measles outbreak in the United States after an importation: challenges and economic impact. J. Infect. Dis. 2011; 203(11): 1517–25. https://doi.org/10.1093/infdis/jir115
  27. Choi W.S., Sniadack D.H., Jee Y., Go U.Y., So J.S., Cho H., et al. Outbreak of measles in the Republic of Korea, 2007: importance of nosocomial transmission. J. Infect. Dis. 2011; 204(Suppl. 1): S483–90. https://doi.org/10.1093/infdis/jir087
  28. Davidson N., Andrews R., Riddell М., Leydon J., Lynch P. Outbreak investigation team. А measles outbreak among young adults in Victoria, February 2001. Commun. Dis. Intell. Q. Rep. 2002; 26(2): 273–8.
  29. Marshall T.M., Hlatswayo D., Schoub B. Nosocomial outbreaks – a potential threat to the elimination of measles. J. Infect. Dis. 2003; 187(Suppl. 1): S97–101. https://doi.org/10.1086/368041
  30. Remington P.L., Hall W.N., Davis I.H., Herald A., Gunn R.A. Airborne transmission of measles in a physician’s office. JAMA. 1985; 253(11): 1574–7.
  31. Weston K.M., Dwyer D.E., Ratnamohan M., McPhie K., Chan S.W., Branley J.M., et al. Nosocomial and community transmission of measles virus genotype D8 imported by a returning traveller from Nepal. Commun. Dis. Intell. Q. Rep. 2006; 30(3): 358–65.

Copyright (c) 2022 Kostinov M.P., Zhuravlev P.I., Loktionova M.N., Shmitko A.D., Polishchuk V.B., Tatarinchik A.A., Smirnova O.A., Fursov I.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies